ArticleMolecular biology reports2025
Evaluation of the effect of Fe-Ni nanoparticles on apoptosis through the modulation of miR-212-3p, miR-221-3p, BAX, and BCL-2 genes in pancreatic PANC-1 cells.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is known to be one of the most challenging and complex types of cancer owing to its late diagnosis, rapid growth, and resistance to treatment. The use of iron-nickel (Fe-Ni) nanoparticles in cancer treatment is an innovative method that can reduce side effects. This study investigates the anticancer effects of Fe-Ni nanoparticles on the activity of the PANC-1 cell line.
methodsIn this experimental study, after synthesizing Fe-Ni nanoparticles, their characterization was performed using UV-vis spectroscopy, TEM, and FE-SEM imaging. Subsequently, pancreatic cancer cells (PANC-1 cell line) and normal HUVEC were treated with these nanoparticles. Based on the obtained IC
resultThe characterization results of the nanoparticles indicated that the Fe-Ni nanoparticles were within the optimal range for therapeutic applications in terms of shape and size. The IC50 for PANC-1 cells was 50.17 µg/mL at 24 h and 28.59 µg/mL at 48 h. In contrast, the IC50 for HUVEC cells exceeded 200 µg/mL at both time points, indicating selective toxicity toward cancer cells. The findings revealed that the treatment of pancreatic cancer cells with Fe-Ni nanoparticles significantly reduced cell survival and induced apoptosis. Additionally, the nanoparticles modulated the genes involved in apoptosis and disrupted the expression of miR-221-3p and miR-212-3p, demonstrating further effects on this cell line.
conclusionFinally, the anticancer effects of Fe-Ni nanoparticles revealed that these nanoparticles can exhibit selective toxicity towards cancer cells and possess the ability to induce apoptosis.
Indexed as
Identifiers
41166020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.